July 9, 2008-Mundipharma announced today that Targin, an oral prolonged-release oxycodone / naloxone combination tablet, has been submitted for regulatory approval in Europe.
Targin(r) is a combination of a strong opioid receptor agonist, oxycodone, and a locally acting opioid receptor antagonist, naloxone. The oxycodone provides the analgesic effect, while the naloxone, exerting its effect only in the gut (before being eliminated by the liver), prevents the onset of opioid induced constipation (OIC) through blockade of the opioid receptors found in the gut.
The details can be read here.
No comments:
Post a Comment